ALK and neuroblastoma: The genomic landscape of NB is well-studied with only a few genes shown to be altered recurrently by somatic genetic events, where mutations in ALK, encoding a receptor tyrosine kinase, being the most frequent; ~ 10% at primary diagnosis [4–6] and in 20–43% of patients with relapsed or refractory NB [7–9].